Journal
CLINICAL INFECTIOUS DISEASES
Volume 75, Issue 3, Pages 519-521Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciab1061
Keywords
Clostridioides difficile; formulary; vancomycin; fidaxomicin
Categories
Ask authors/readers for more resources
This study reviewed the discharge of Clostridioides difficile-positive patients treated with fidaxomicin after local adoption of the 2021 CDI guidelines. From June 14 to October 3, 2021, 80% (12/15) of the patients had copayments ranging from $0 to $35, and 27% (4/15) required prior authorization. The 30-day CDI recurrence rate was 7%.
We reviewed Clostridioides difficile-positive patients discharged on fidaxomicin after local adoption of 2021 C. difficile infection (CDI) guidelines. From 14 June to 3 October 2021, 80% (12/15) had copayments of $0-$35 and 27% (4/15) required prior authorization. The 30-day CDI recurrence was 7%.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available